A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab항 활성화 인자 XII 단일 클론 항체 garadacimab의 I 상, 최초 인간, 무작위 용량 증량 연구Clinical Trial Published on 2022-03-012022-09-12 Journal: Clinical and translational science [Category] MERS, 임상, 진단, [키워드] activated activities Analysis antibodies blood sample clinical development Coagulation Cohort cohorts collected Contact coronavirus disease COVID-19 deaths demonstrated dose dose-dependent dose-dependent manner dose-escalation Effect eight Factor healthy healthy volunteers increase in increases in inhibit intravenous male monoclonal antibody MOST pathway Phase I Placebo plasma plasma concentration positive proinflammatory Prothrombin time prothrombotic Randomized reported single-center Support TEAE TEAEs tested Tolerability treatment-emergent adverse event Volunteer volunteers [DOI] 10.1111/cts.13180 PMC 바로가기 [Article Type] Clinical Trial
A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice명반을 포함하는 RBD 기반 COVID-19 백신 제형의 새로운 박테리아 프로테아제 억제제 보조제는 중화 항체, 특정 배아 중심 B 세포를 증가시키고 마우스에서 SARS-CoV-2 감염에 대한 보호를 제공합니다Article Published on 2022-02-282022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus addition adjuvant adjuvants Against Alpha alum Antigen B cell Brucella CD8 center clinical development Combination composed Containing coronavirus COVID-19 evaluated Formulation Frequency Germinal Germinal center germinal center cells increase intranasal K18-hACE2 mice Lungs mucosal neutralization capacity neutralizing antibody novel plasmablasts Protease inhibitor protection RBD Receptor binding domain respiratory Result SARS- CoV-2 SARS-CoV-2 significantly increased Specific spleen T-cell Response T-cell responses Th1 the vaccine U-Omp19 Vaccine variant virus [DOI] 10.3389/fimmu.2022.844837 PMC 바로가기 [Article Type] Article
Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection흡입형 렘데시비르는 SARS-CoV-2 감염의 비인간 영장류 모델에서 바이러스 부담을 줄입니다Article Published on 2022-02-232022-09-11 Journal: Science Translational Medicine [Category] COVID19(2023년), SARS, 치료제, [키워드] Administered administration African green monkey African green monkeys AGM alternative route approved Bronchoalveolar lavage fluid clinical benefit clinical development comparable Concentration coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated disease dose Efficacy Emergency use evaluated followed by green hospitalized COVID-19 patients hours post-infection inhalation Inhaled intravenous investigated IV administration lower dose Lower respiratory tract metabolite nucleotide once daily Patient pharmacokinetics Placebo produced RDV reduce reductions reductions in relative Remdesivir repeated respiratory tract tissue respiratory tract tissues SARS-COV-2 infection Support tissues Treatment triphosphate upper respiratory tract US FDA viral burden viral replication [DOI] 10.1126/scitranslmed.abl8282 PMC 바로가기 [Article Type] Article
A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection새로운 글루코코르티코이드 및 안드로겐 수용체 조절제는 SARS-CoV-2 감염의 시리아 햄스터 모델에서 바이러스 진입 및 선천성 면역 염증 반응을 감소시킵니다Immunology Published on 2022-02-162022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, 치료제, [키워드] 2019-nCoV 2019-nCoV/USA-WA1/2020 ACE2 acting Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered administration amplify Analysis androgen Androgen receptor angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 animal animals antagonist antagonists bind caused CD4 Cell clinical development Clinical studies clinical study coronavirus COVID-19 Critical days post-infection decrease Defense domain dose-dependent DPI Efficacy enzyme examined expression glucocorticoid Glucocorticoid receptor golden hamster hamster Host host defense humans IL-6 indicated infiltration Inflammation inflammatory lung injury Inflammatory response Innate innate immune Innate immunity intranasally lack lung Lung histopathology Lung injury lung tissue Macrophage macrophages mechanism mechanism of action Model modulator molecular docking studies Molecular docking study novel oral administration outcome patients Phylogenetic analysis positive Predictive Prevent progression protease Protein PT150 receptor receptors reduce regulated Replication replication of SARS-CoV-2 required Research respiratory response Result SARS – CoV – 2 SARS-CoV-2 SARS-COV-2 infection sequence identity Serine serine 2 severe acute respiratory syndrome Coronavirus shown strain surface protein T-cell T-cells TCID the cell therapeutic therapeutic efficacy Therapeutics tissue damage tissue injury TMPRSS2 transcriptional repressor transcriptionally transmembrane Treatment USA-WA1/2020 variants variants of SARS-CoV-2 Viral viral entry Viral load virus were infected [DOI] 10.3389/fimmu.2022.811430 PMC 바로가기 [Article Type] Immunology
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern경구 프로테아제 억제제(PF-07321332)는 우려되는 SARS-CoV-2 변종 감염으로부터 시리아 햄스터를 보호합니다Article Published on 2022-02-152022-09-10 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] 3CLpro Air-liquid interface Alpha Alpha variant animals Anti-viral Antiviral Antiviral agents B.1.351 B.1.617.2 Beta clinical development clinical trials dosed epithelial cell epithelial cells Evidence evidence of golden hamster golden hamsters hamster in vitro activity Infection infection with SARS-CoV-2 inhibitor intranasal MPro PF-07321332 Pfizer prevented primary human airway Primary human airway epithelial cells protease Protease inhibitor PROTECT reduced Replication SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants selective Syrian Golden hamsters target Transmission Treatment variant variants of concern Viral viral replication [DOI] 10.1038/s41467-022-28354-0 PMC 바로가기 [Article Type] Article
COVID-19 Vaccines: An Overview of Different PlatformsReview Published on 2022-02-122022-10-28 Journal: Bioengineering [Category] COVID-19, [키워드] approach approved boost clinical development Clinical efficacy conducted Course COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines determine DNA vaccines effective Effectiveness Efficacy evaluate immune IMPROVE Inactivated Vaccines literature review mRNA Mutation new SARS-CoV-2 patient groups peptides platform prevention Research RNA RNA vaccine shown single vaccination stability subunit vaccination Vaccine Vaccine development variant vector virus [DOI] 10.3390/bioengineering9020072 PMC 바로가기 [Article Type] Review
Development of plant-made monoclonal antibodies against viral infectionsReview article Published on 2022-02-012022-10-05 Journal: Current opinion in virology [Category] 비임상, [키워드] addition Anti-viral antibody benefit binding candidate clinical development current development expression vector Fc receptors homogeneity mAb mammalian monoclonal antibody novel offer Pandemics plant unique viral infection [DOI] 10.1016/j.coviro.2021.12.005 [Article Type] Review article
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 TreatmentReview Published on 2022-01-252022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, SARS, [키워드] clinical development cofactor coronavirus COVID-19 epithelial cell expression gastrointestinal tract glycoprotein Influenza inhibiting other organs other respiratory virus physiological Prostate protease Protease inhibitor respiratory viruses SARS-CoV-2 SARS-CoV-2 entry substrate target TMPRSS2 TMPRSS2 inhibitor transmembrane Treatment viral infection [DOI] 10.3390/ijms23031351 PMC 바로가기 [Article Type] Review
The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAsPDE4 억제제인 Tanimilast는 SARS-CoV-2 ssRNA에 의한 전염증성 수지상 세포 활성화를 둔화시킵니다Immunology Published on 2022-01-242022-09-11 Journal: Frontiers in Immunology [Category] 치료법, [키워드] acquisition activate activated DCs Activation anti-inflammatory drug approved atopic dermatitis blocked CCL3 CCR7 CD4 CD8 CD83 CD86 cDCs chemokine chemokines CHF6001 clinical development Clinical studies COPD COVID-19 CXCL10 CXCL9 cytokine Cytokines DCs demonstrated dendritic cell did not reduce disease dysregulation genomic homing receptor hyperinflammation IL-12 IL-6 immune dysregulation immune response immunomodulatory immunomodulatory drug immunomodulatory drugs impair Inflammatory inflammatory conditions Inhaled inhibitor International Lymph node lymph node homing marker maturation MHC-I MHC-II modulate non-proprietary name pDCs phenotype phosphodiesterase phosphodiesterase 4 (PDE4) inhibitors pro-inflammatory pro-inflammatory cytokine pro-inflammatory cytokines proinflammatory cytokines proliferation psoriasis receptor SARS-CoV-2 SARS-COV-2 infection scenario selective skewed ssRNA steroid T cell T cells Tanimilast Th2 TNF-α treat Treatment type I IFNs [DOI] 10.3389/fimmu.2021.797390 PMC 바로가기 [Article Type] Immunology
PROTAC targeted protein degraders: the past is prologue Reviews Published on 2022-01-182022-10-05 Journal: Nature Reviews Drug Discovery [Category] 신약개발, 치료제, [키워드] Cancer clinical development Degradation degrade disease-causing oncology Precision Protein provided reported review Small molecules target target protein therapeutic ubiquitin ligase [DOI] 10.1038/s41573-021-00371-6 [Article Type] Reviews